Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.83 |
| ▸ | MAP3K7 | O43318 | 8/20 | 0.83 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 0.83 |
| ▸ | MAP3K20 | Q9NYL2 | 7/20 | 0.83 |
| ▸ | CSK | P41240 | 5/20 | 0.83 |
| ▸ | ABL1 | P00519 | 4/20 | 0.83 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.83 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.83 |
| ▸ | RAF1 | P04049 | 2/20 | 0.83 |
| ▸ | LYN | P07948 | 2/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.83 |
| ▸ | ABL2 | P42684 | 2/20 | 0.83 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.83 |
| ▸ | FES | P07332 | 1/20 | 0.68 |
| ▸ | FER | P16591 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284678 | 1.00 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284669 | 1.00 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284518 | 0.91 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284510 | 0.91 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL29725987 | 0.91 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL16786132 | 0.88 | MAPK14 (0.95) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2285546 | 0.86 | DDR1 (0.71) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL14702344 | 0.85 | DDR1 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL17208651 | 0.82 | MAPK14 (0.69) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL17208714 | 0.82 | BRAF (0.76) | KMT2AATMEGFRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118319866-A | Formulations comprising RET kinase inhibitors | 罗索肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118234498-A | STING modulators, compositions, and methods of use thereof | 南佛罗里达大学 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024020534-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4308573-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-111971286-B | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2023034587-A1 | STING Modulators, Compositions, and Methods of Use | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4081526-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-111278822-B | Crystalline forms | 阿雷生物药品公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-4069369-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022197898-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022164789-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS | SCHRÖDINGER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-4021449-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | University of South Florida (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022055963-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | MAPK14 856/4885MAP3K7 434/4885MAP4K2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.